- Home
- CCTG vs BLRX Comparison
CCTG vs BLRX Comparison
Compare CCTG & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCTG
- BLRX
- Stock Information
- Founded
- CCTG 1993
- BLRX 2003
- Country
- CCTG Hong Kong
- BLRX Israel
- Employees
- CCTG N/A
- BLRX N/A
- Industry
- CCTG
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- CCTG
- BLRX Health Care
- Exchange
- CCTG Nasdaq
- BLRX Nasdaq
- Market Cap
- CCTG 14.9M
- BLRX 15.3M
- IPO Year
- CCTG 2024
- BLRX 2011
- Fundamental
- Price
- CCTG $1.10
- BLRX $4.45
- Analyst Decision
- CCTG
- BLRX Strong Buy
- Analyst Count
- CCTG 0
- BLRX 2
- Target Price
- CCTG N/A
- BLRX $19.00
- AVG Volume (30 Days)
- CCTG 5.9K
- BLRX 252.1K
- Earning Date
- CCTG 08-23-2025
- BLRX 08-14-2025
- Dividend Yield
- CCTG N/A
- BLRX N/A
- EPS Growth
- CCTG N/A
- BLRX N/A
- EPS
- CCTG N/A
- BLRX N/A
- Revenue
- CCTG $16,463,490.00
- BLRX $22,340,000.00
- Revenue This Year
- CCTG N/A
- BLRX N/A
- Revenue Next Year
- CCTG N/A
- BLRX N/A
- P/E Ratio
- CCTG N/A
- BLRX N/A
- Revenue Growth
- CCTG 3.27
- BLRX 91.68
- 52 Week Low
- CCTG $0.99
- BLRX $2.30
- 52 Week High
- CCTG $3.17
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- CCTG 45.98
- BLRX 50.17
- Support Level
- CCTG $1.05
- BLRX $3.79
- Resistance Level
- CCTG $1.12
- BLRX $4.62
- Average True Range (ATR)
- CCTG 0.04
- BLRX 0.56
- MACD
- CCTG 0.01
- BLRX -0.13
- Stochastic Oscillator
- CCTG 70.00
- BLRX 21.79
About CCTG CCSC Technology International Holdings Limited
CCSC Technology International Holdings Ltd along with its subsidiaries is involved in the sale, design, and manufacturing of interconnect products, including connectors, cables, and wire harnesses. Its products include customized interconnect products, including connectors, cables, and harnesses that are used for a range of applications in a diversified set of industries, including industrial, automotive, robotics, medical equipment, computer, network and telecommunication, and consumer products. Geographically, the company generates maximum revenue from the sale of its products in Europe and the rest from the Americas and Asia.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.